Zhejiang Starry Pharm Co Ltd (603520) — Capital Reinvestment Ratio
Zhejiang Starry Pharm Co Ltd (603520) has a Capital Reinvestment Ratio of 2.67x as of September 2025, meaning it reinvests 3% of its operating cash flow (CN¥9.76 Million) in capital expenditures (CN¥26.10 Million). Check 603520 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Starry Pharm Co Ltd Capital Reinvestment Ratio (2012–2025)
This chart tracks Zhejiang Starry Pharm Co Ltd's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see Zhejiang Starry Pharm Co Ltd cash conversion from operations.
Annual Capital Reinvestment Ratio for Zhejiang Starry Pharm Co Ltd (2012–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Starry Pharm Co Ltd from 2012 to 2025. See Zhejiang Starry Pharm Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 73.42x | CN¥3.67 Million | CN¥269.20 Million | ▲ +2855.8% |
| 2024 | 2.48x | CN¥193.50 Million | CN¥480.62 Million | ▼ -57.0% |
| 2023 | 5.77x | CN¥46.13 Million | CN¥266.22 Million | ▲ +866.5% |
| 2021 | 0.60x | CN¥508.84 Million | CN¥303.88 Million | ▼ -32.0% |
| 2020 | 0.88x | CN¥174.48 Million | CN¥153.17 Million | ▲ +62.5% |
| 2019 | 0.54x | CN¥246.77 Million | CN¥133.28 Million | ▼ -36.2% |
| 2018 | 0.85x | CN¥191.84 Million | CN¥162.40 Million | ▼ -83.1% |
| 2017 | 5.01x | CN¥18.10 Million | CN¥90.62 Million | ▼ -79.6% |
| 2016 | 24.55x | CN¥7.68 Million | CN¥188.51 Million | ▲ +851.9% |
| 2015 | 2.58x | CN¥94.88 Million | CN¥244.66 Million | ▲ +79.6% |
| 2014 | 1.44x | CN¥144.00 Million | CN¥206.76 Million | ▼ -42.9% |
| 2013 | 2.51x | CN¥74.99 Million | CN¥188.42 Million | ▲ +87.8% |
| 2012 | 1.34x | CN¥103.34 Million | CN¥138.28 Million | — |